具核梭杆菌通过激活E-钙黏蛋白/β-连环蛋白信号通路上调ABCG2促进结直肠癌奥沙利铂耐药
该研究探讨具核梭杆菌是否通过调控ABCG2影响结直肠癌奥沙利铂耐药。体外实验显示具核梭杆菌共培养提高奥沙利铂处理后的结直肠癌细胞相对存活率,敲低ABCG2或阻断E-钙黏蛋白/β-连环蛋白通路可逆转此效应;裸鼠体内实验显示ABCG2阻断剂降低肿瘤重量。结论为具核梭杆菌通过E-钙黏蛋白/β-连环蛋白信号通路上调ABCG2表达诱导结直肠癌对奥沙利铂耐药。
要点
- 具核梭杆菌+奥沙利铂组细胞相对存活率高于奥沙利铂组(HT-29:92.26% vs 79.64%;HCT-116:82.13% vs 67.56%,均P<0.001)。
- 敲低ABCG2的HCT-116细胞在奥沙利铂和具核梭杆菌共培养下相对存活率61.44%,低于未敲低组的69.29%(P=0.015)。
- 裸鼠体内F.n+L-OHP+TCBZSO组肿瘤重量0.12g,低于F.n+L-OHP组的0.33g(P<0.001)。
核心结论
- 具核梭杆菌通过E-钙黏蛋白/β-连环蛋白信号通路上调ABCG2表达,促进结直肠癌对奥沙利铂耐药。
研究设计与样本
- 利用奥沙利铂干预结直肠癌细胞并与具核梭杆菌共培养建立微生物感染的化疗诱导模型。
- 通过构建shRNA质粒敲低目的基因,构建HCT-116细胞具核梭杆菌感染模型并进行转录组测序及KEGG和GO分析。
- 使用金雀异黄酮作为E-钙黏蛋白阻断剂,三氯苯达唑亚砜(TCBZSO)作为ABCG2阻断剂。
- 构建裸鼠皮下移植瘤模型,免疫组化检测肿瘤组织中ABCG2蛋白表达水平。
主要发现
- CCK-8显示具核梭杆菌+奥沙利铂组细胞相对存活率高于奥沙利铂组(HT-29:92.26% vs 79.64%;HCT-116:82.13% vs 67.56%,均P<0.001)。
- 敲低ABCG2的HCT-116细胞在奥沙利铂和具核梭杆菌共培养下相对存活率61.44%,低于未敲低组的69.29%(P=0.015)。
- GO富集分析显示与具核梭杆菌共培养的HCT-116细胞在β-catenin结合、钙黏蛋白结合、Wnt信号通路调控显著富集。
- F.nucleatum+金雀异黄酮组ABCG2 mRNA相对表达水平较F.nucleatum组降低(P<0.001)。
- 体内实验显示F.n+L-OHP+TCBZSO组裸鼠肿瘤重量0.12g,低于F.n+L-OHP组的0.33g(P<0.001);免疫组化提示TCBZSO干预后阻断了具核梭杆菌对ABCG2蛋白表达的促进作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate whether F.nucleatum affects the chemotherapy resistance of colorectal cancer by regulating ABC subfamily G subtype 2 (ABCG2), in view of the fact that the correlation between the two has not been reported. Methods: Oxaliplatin was used to interfere with colorectal cancer cells and co-cultured with F.nucleatum to establish a chemotherapy-induced model of microbial infection. Calcein AM/PI cell staining, trypan blue staining, and cell counting kit 8 (CCK-8) method were used to detect cell activity. Real-time fluorescence quantitative polymerase chain reaction and western blot were used to detect ABCG2 mRNA and protein expression levels in colorectal cancer cells. The target gene was knocked down by constructing shRNA plasmids. The HCT-116 cell F.nucleatum infection model was constructed and transcriptome sequencing and Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) analyses were performed to determine the differential gene expression enrichment pathways. Genistein (GST) was used as an E-cadherin blocker, and triclabendazole sulfoxide (TCBZSO) was used as an ABCG2 blocker. Immunofluorescence was used to detect E-cadherin and β-catenin protein expressions and intracellular localization levels. The subcutaneous xenograft model of nude mice was constructed in vivo, and the expression level of ABCG2 protein in tissues was detected by immunohistochemical staining. Results: CCK-8 results showed that F. nucleatum+oxaliplatin group [HT-29, (92.26±1.66)%; HCT-116, (82.13±1.84)%] cell relative survival rate was higher than that of oxaliplatin group [HT-29, (79.64±3.72)%; HCT-116, (67.56±2.96)%; P<0.001]. The relative survival rate of oxaliplatin and F. nucleatum co-culture group with ABCG2-knockdown HCT-116 cells [(61.44±1.48)%] was lower than that of F. nucleatum and oxaliplatin co-cultured with HCT-116 cells [(69.29±4.45)%, P=0.015]. GO enrichment analysis showed that HCT-116 cells co-cultured with F.nucleatum were significantly enriched in "β-catenin binding", "cadherin binding" and "regulation of Wnt signaling pathway". RT-qPCR results showed that the relative expression of ABCG2 mRNA in F.nucleatum + genistein group was significantly lower than that in F.nucleatum group (P<0.001). The results in vivo showed that the tumor weight in the F.n+L-OHP+TCBZSO group [(0.12±0.02)g] was lower than that in the F.n+L-OHP group [(0.33±0.05)g, P<0.001]. Immunohistochemistry suggested that the promotion of ABCG2 protein expression by F. nucleatum was blocked after TCBZSO intervention. Conclusion: F. nucleatum up-regulates ABCG2 expression through E-cadherin/β-catenin signaling pathway to promote colorectal cancer resistance to oxaliplatin. 目的: 探讨肠道致病菌具核梭杆菌(F.nucleatum)是否通过调控 ABC亚家族G亚型2(ABCG2)从而影响结直肠癌化疗耐药。 方法: 利用奥沙利铂干预结直肠癌细胞并与F.nucleatum共培养建立微生物感染的化疗诱导模型,Calcein AM/PI活/死细胞染色、锥虫蓝染色、细胞计数试剂盒8(CCK-8)法检测细胞活性,实时荧光定量聚合酶链反应和Western blot法检测结直肠癌细胞中ABCG2 mRNA和蛋白表达水平。通过构建shRNA质粒进行目的基因敲减。构建HCT-116细胞F.nucleatum感染模型并进行转录组测序和差异基因京都基因与基因组百科全书和基因本体论分析。利用金雀异黄酮作为E-cadherin阻断剂,三氯苯达唑亚砜(TCBZSO)作为ABCG2阻断剂,免疫荧光检测E-cadherin和β-catenin蛋白表达及细胞内定位水平。构建裸鼠皮下移植瘤模型,免疫组化染色检测肿瘤组织中ABCG2蛋白表达水平。 结果: CCK-8结果显示,F.nucleatum+奥沙利铂组细胞相对存活率[HT-29:(92.26±1.66)%;HCT-116:(82.13±1.84)%]高于奥沙利铂组[HT-29:(79.64±3.72)%;HCT-116:(67.56±2.96)%,均P<0.001];奥沙利铂和F.nucleatum与敲低ABCG2的HCT-116细胞共培养组细胞相对存活率[(61.44±1.48)%]低于与F.nucleatum和奥沙利铂共培养组[(69.29±4.45)%,P=0.015]。富集分析提示,与F.nucleatum共培养后的HCT-116细胞β-catenin结合、钙黏蛋白结合、Wnt信号通路的调控显著富集。F.nucleatum+金雀异黄酮组ABCG2 mRNA相对表达水平较F.nucleatum组降低(P<0.001)。体内实验结果显示,F.n+L-OHP+TCBZSO组裸鼠肿瘤重量[(0.12±0.02)g]低于F.n+L-OHP组[(0.33±0.05)g,P<0.001]。免疫组化提示,TCBZSO干预后阻断了F.nucleatum对ABCG2蛋白表达的促进作用。 结论: F.nucleatum通过E-cadherin/β-catenin 信号通路上调ABCG2的表达诱导结直肠癌对奥沙利铂耐药。.
引用
- Xu FQ, Li BW, Liu Y, et al. [Fusobacterium nucleatum upregulates ABCG2 by activating the E-cadherin/β-catenin signaling pathway to promote oxaliplatin resistance in colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40268550. doi:10.3760/cma.j.cn112152-20240719-00297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。